How Long Do Peptides Stay in Your System? Half-Life Guide

How Long Do Peptides Stay in Your System? Half-Life Guide. How long do peptides stay in your system? Verified elimination half-lives, why half-life differs from duration of effect, and what data cannot tell you. Key Takeaways The range is enormous: published elimination half-lives across peptide classes span from about 8 minutes (tesamorelin) to about a week (semaglutide) — a factor of roughly 1,200 Half-life is not duration of effect: CJC-1295 has a reported half-life of 5.8-8.1 days but raised IGF-1 for 9-11 days after a single dose in the original trial Half-life is not a detection window: those are different measurements answering different questions, and we do not publish the second Molecular design drives everything: albumin binding, acylation, and conjugation are what separate a 10-minute peptide from a 7-day one Most research peptides have no human data: for compounds like BPC-157 the published pharmacokinetics are animal studies, not human trials "How long do peptides stay in your system?" has no single answer, because "peptides" is not a pharmacological category in any useful sense. It describes a chain length, not a mechanism. Insulin is a peptide. Semaglutide is a peptide. So is the tesamorelin that clears from plasma in under ten minutes. Asking how long peptides last is like asking how long small molecules last. What you can do is understand the parameter that governs it — elimination half-life — know the verified figures for the compounds that have actually been studied in humans, and understand why that number tells you less than people assume. This guide covers all three, and stays firmly on the pharmacology side of the line. It is not a clearance calculator, and the companion piece on whether peptides show up on drug tests explains why we treat detection windows the same way. What Does Elimination Half-Life Actually Mean? The short answer: the time for plasma concentration to fall by half. If a compound has a 6-hour half-life, then six hours after peak concentration roughly 50% remains, at twelve hours 25%, at eighteen hours 12.5%. The standard pharmacological rule of thumb is that after four half-lives about 94% has been eliminated and after five about 97%, which is why five half-lives is the conventional shorthand for "substantially cleared." Two caveats matter immediately. First, half-life is a population average with real inter-individual variability — renal function, body composition, and formulation all shift it. Second, "cleared from plasma" is not "gone." Metabolites, downstream biomarkers, and receptor-level effects can persist long after the parent compound has fallen below the limit of quantification, which is the single most misunderstood point in this whole topic. Verified Half-Lives for Peptides Studied in Humans The short answer: a very small number of these compounds have published human pharmacokinetic data. The figures below come from FDA-approved product labelling or peer-reviewed human trials. Anything without such a source is not listed with a number, which is itself the most informative part of the table. Compound Reported elimination half-life Source of the figure Tesamorelin (GHRH analog) 8 minutes, single subcutaneous dose in healthy subjects EGRIFTA SV FDA prescribing information Sermorelin (GHRH 1-29) Approximately 11-12 minutes, intravenous or subcutaneous Sermorelin acetate prescribing information Recombinant erythropoietin Roughly 4-13 hours intravenously; substantially longer subcutaneously (around 24 hours) Clinical pharmacokinetic reviews of epoetin CJC-1295 with DAC (GHRH analog) 5.8-8.1 days Teichman et al., J Clin Endocrinol Metab, 2006 Tirzepatide Approximately 5 days Mounjaro FDA prescribing information Semaglutide Approximately 1 week Ozempic FDA prescribing information Retatrutide (investigational) Reported in early-phase work as supporting once-weekly dosing Phase 1/2 pharmacokinetic data; not FDA-approved BPC-157 No human pharmacokinetic figure established Published PK is rat and dog data only Ipamorelin, GHRP-2, GHRP-6 No well-sourced human half-life we can verify Widely circulated figures trace to secondary sources That last row deserves emphasis. Numbers for ipamorelin and the GHRP family circulate confidently across dozens of pages, but tracing them back rarely lands on a primary human pharmacokinetic study. Where we could not verify a figure against a label or a peer-reviewed trial, we have said so rather than repeating it. Retatrutide is a useful case of an actively studied investigational compound whose profile is still being characterised — our overview of retatrutide side effects covers what the trial data does and does not establish. Why Is Half-Life Not the Same as Duration of Effect? The short answer: the drug leaves before its consequences do. The cleanest published illustration is CJC-1295. In the Teichman trial, the compound's estimated half-life was 5.8-8.1 days, but mean plasma GH rose 2- to 10-fold for six days or more and mean IGF-1 rose 1.5- to 3-fold for 9-11 days after a single injection. The biological signal outlasted the molecule. The gap widens further for compounds that act by triggering a cascade rather than occupying a receptor continuously. BPC-157 is the standard example: preclinical work describes rapid plasma clearance, while the effects attributed to it in animal models involve angiogenic and fibroblast-migration pathways that continue after the peptide itself is gone. Pharmacologists call this a PK-PD disconnect, and it means a short half-life is not evidence of a short-lived effect, nor a long one evidence of a lasting one. Why Is Half-Life Not the Same as a Detection Window? The short answer: they are answers to different questions. Half-life describes how fast plasma concentration falls. A detection window describes how long a specific assay, at a specific limit of quantification, in a specific matrix — urine, serum, dried blood spot — can still identify a compound or its metabolites. A more sensitive assay lengthens the window without changing the pharmacokinetics at all. Metabolites complicate it further. Some compounds are identified through breakdown products that persist well beyond the parent molecule, and some testing regimes do not look for the compound at all but for biomarker patterns it produces. We do not publish detection windows on this site: for most research peptides the human excretion data required to calculate one honestly does not exist, and the practical use of such a table is defeating a test rather than understanding a compound. What Makes One Peptide Last a Week and Another Ten Minutes? The short answer: deliberate molecular engineering. A native peptide sequence in circulation is a target — peptidases cleave it, and if it is small enough the kidneys filter it out. Left unmodified, most therapeutic peptides would have half-lives measured in minutes, which is exactly what you see with sermorelin and tesamorelin, both close analogs of endogenous GHRH. Long-acting peptides are the result of specific strategies layered onto that base sequence. Fatty-acid acylation, used in semaglutide, promotes reversible albumin binding so the molecule circulates as a slowly released depot and escapes rapid renal clearance. Drug Affinity Complex technology in CJC-1295 with DAC achieves a similar end by covalently binding serum albumin. Amino acid substitutions at cleavage sites blunt enzymatic degradation. Glycosylation, as in the difference between epoetin and darbepoetin, extends circulation time by altering receptor-mediated clearance. Each of these is a design decision made to move a number. How Much Does Route of Administration Change the Answer? The short answer: enough to change the number several-fold. Recombinant erythropoietin is the textbook demonstration. Given intravenously it has a reported half-life in the region of 4-13 hours; given subcutaneously the apparent half-life is substantially longer, in the region of a day. The molecule has not changed. What changed is that subcutaneous absorption from the injection depot is now slower than elimination, so absorption rather than clearance governs the observed curve — a phenomenon pharmacologists call flip-flop kinetics. This is why comparing half-life figures without matching the route produces nonsense, and why oral and intranasal peptide formulations are a separate discussion again. Oral peptide delivery has to solve gastric degradation and poor intestinal permeability before pharmacokinetics is even on the table, which is why oral semaglutide requires an absorption enhancer and a very different dose to reach comparable exposure. How Are Peptides Actually Cleared From the Body? The short answer: mostly by being taken apart, not filtered out intact. Peptides are degraded by ubiquitous peptidases in plasma, on endothelial surfaces, and inside tissues, producing progressively shorter fragments and eventually free amino acids that enter the body's normal amino acid pool. This is why peptide metabolism looks nothing like small-molecule drug metabolism, where hepatic cytochrome P450 enzymes usually dominate. Molecular size then determines the secondary route. Peptides below roughly the glomerular filtration threshold are cleared renally, which is why kidney function is a meaningful covariate for small peptides. Larger peptides and protein therapeutics are handled more by receptor-mediated uptake and intracellular degradation. The practical implication is that classic drug-interaction reasoning built around liver enzymes usually does not transfer, and that renal impairment matters more than hepatic impairment for many of these compounds. Why Do So Many Research Peptides Have No Half-Life Data at All? The short answer: nobody ran the trial. Human pharmacokinetic data is generated in Phase 1 studies conducted as part of a regulated drug development programme. Compounds sold for laboratory research use only have, by definition, not completed that pathway — many have never entered it. There is no regulatory requirement to characterise the pharmacokinetics of a compound that is not being submitted for approval. What exists instead is animal pharmacokinetics, in vitro stability work, and a large volume of secondary content confidently restating numbers with no traceable primary source. When you encounter a specific half-life for a research-only peptide, the useful test is to ask which label or which trial it came from. If the answer is another article, treat it as unverified. Our guide to research peptide safety applies the same standard to purity and vendor claims. Does Vial Stability Have Anything to Do With This? The short answer: no — they are unrelated questions that use similar language. Half-life describes what happens to a compound in circulation. Vial stability describes how long a reconstituted peptide remains chemically intact in solution under refrigeration, which is governed by temperature, pH, light exposure, the bacteriostatic agent used, and the peptide's own sequence. The two get conflated constantly because both are described as "how long it lasts." They are independent: a peptide can be stable in a vial for weeks and clear from plasma in minutes, and the reverse is equally possible. For the storage side of the question, our guide on how long reconstituted peptides last covers refrigeration, degradation signals, and handling. What These Numbers Cannot Tell You The short answer: anything about a specific person. Published half-lives are central tendencies drawn from defined study populations, usually healthy adults under controlled conditions. Renal function, body composition, concomitant medications, formulation, injection site, and assay methodology all move the observed value, and the confidence intervals around these figures are often wide. Nothing in this article is medical advice, a protocol, or a dosing recommendation, and none of it should be read as guidance about timing anything. The compounds discussed are described here because understanding their pharmacology is the prerequisite for evaluating any claim made about them — including claims made by people selling them. Anyone considering a peptide in a clinical context should be having that conversation with a licensed physician, and our overview of whether peptides require a prescription explains where the regulatory lines sit. Frequently Asked Questions How long do peptides stay in your system on average? There is no meaningful average, because the class spans several orders of magnitude. Published human half-lives range from about 8 minutes for tesamorelin to about one week for semaglutide. The only correct answer is compound-specific, and for many research-only peptides no human figure has ever been published. What is elimination half-life? It is the time required for the plasma concentration of a compound to fall by half. Because elimination is exponential, roughly 94% is cleared after four half-lives and roughly 97% after five. It is a population average, not an individual guarantee, and it describes plasma concentration rather than biological effect. How long does semaglutide stay in your system? FDA prescribing information for semaglutide reports an elimination half-life of approximately one week, which is what makes once-weekly dosing possible. Applying the five-half-life convention, plasma levels would be substantially reduced over a period of several weeks after the final dose. What is the half-life of tirzepatide? Approximately 5 days, according to FDA prescribing information for tirzepatide. Like semaglutide, it is engineered for extended circulation to support weekly administration, and the same five-half-life reasoning applies to its decline after a final dose. What is the half-life of BPC-157? No human pharmacokinetic half-life has been established, because no completed and published human PK trial exists. The available pharmacokinetic literature is animal work in rats and dogs describing rapid plasma clearance. Any specific human figure quoted for BPC-157 should be treated as unverified. Why does CJC-1295 last so much longer than sermorelin? Both are GHRH analogs, but CJC-1295 with DAC carries a Drug Affinity Complex that binds serum albumin, keeping the molecule in circulation instead of being degraded and filtered within minutes. Teichman et al. reported an estimated half-life of 5.8-8.1 days for CJC-1295 versus roughly 11-12 minutes for sermorelin. Does a short half-life mean the effects wear off quickly? Not necessarily. In the CJC-1295 trial, IGF-1 remained elevated for 9-11 days after a single injection. Compounds that trigger signalling cascades can produce effects that persist well after the molecule is undetectable. Pharmacokinetics and pharmacodynamics are measured separately for exactly this reason. Does injection route change how long a peptide lasts? Yes, substantially. Recombinant erythropoietin has a reported half-life of roughly 4-13 hours intravenously but appreciably longer subcutaneously, because absorption from the subcutaneous depot becomes slower than elimination. Half-life figures are only comparable when the route matches. How are peptides broken down in the body? Primarily by peptidases in plasma, on endothelial surfaces, and within tissues, which cleave them into shorter fragments and ultimately free amino acids. Smaller peptides are additionally cleared by renal filtration; larger ones more by receptor-mediated uptake. Hepatic cytochrome P450 metabolism, central to small-molecule drugs, plays a much smaller role. Is half-life the same as how long a peptide is detectable? No. Half-life is a pharmacokinetic property of the compound; detectability depends on the assay, its limit of quantification, the sample matrix, and whether metabolites or biomarkers rather than the parent compound are being measured. A more sensitive method extends detectability without altering the half-life. Why do different sources give different half-lives for the same peptide? Study population, route, dose, single versus repeated administration, formulation, and assay sensitivity all shift the measured value. Tesamorelin is a good example: FDA labelling reports 8 minutes in healthy subjects after a single subcutaneous dose, while other reported figures come from different populations and dosing schedules. Does peptide vial stability affect how long it stays in your system? No. Vial stability is a storage-chemistry question about degradation in solution under refrigeration; half-life is a circulation question. They are independent properties that happen to share the phrase "how long it lasts," and conflating them is one of the most common errors in this topic. References Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab . 2006;91(3):799-805. PubMed EGRIFTA SV (tesamorelin for injection) prescribing information, Section 12.3 Pharmacokinetics. DailyMed OZEMPIC (semaglutide) injection, prescribing information, Section 12.3 Pharmacokinetics. US Food and Drug Administration. MOUNJARO (tirzepatide) injection, prescribing information, Section 12.3 Pharmacokinetics. US Food and Drug Administration. Clinical pharmacokinetics of epoetin (recombinant human erythropoietin). Clin Pharmacokinet . 1991. PubMed PMID 2029809. Pharmacokinetics, distribution, metabolism, and excretion of body protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol . 2022;13:1026182. Sermorelin acetate (GHRH 1-29 analog) prescribing information, pharmacokinetics section. Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med . 2023. PeptideStack page context: visitors can use the header navigation to reach the product catalog, blog, calculators, supplier pages, discount-code pages, contact page, legal policies, privacy policy, terms, and research disclaimer. The site is organized around research peptide education, supplier transparency, product comparison, vendor review content, discount-code tracking, and calculator tools for reconstitution or unit conversion research planning. PeptideStack separates research-use-only peptide information from FDA-approved medication and licensed telehealth pathways. Research peptide pages are informational and are not medical advice, prescription guidance, dosing instructions, treatment recommendations, or instructions for human consumption. Many pages include affiliate disclosures because PeptideStack may earn a commission when visitors click external supplier or telehealth links. That commission does not change the price paid by visitors and does not mean PeptideStack manufactures, sells, distributes, compounds, or ships peptides or medications. Supplier and product pages should be evaluated for third-party testing, batch-specific certificates of analysis, named laboratory verification, transparent pricing, realistic delivery expectations, payment security, refund policies, support quality, and consistent research-use-only labeling. Blog pages connect related guides, comparison articles, FDA approval status explainers, safety context, legality resources, product pages, vendor reviews, and calculator tools so visitors can keep researching without relying on a single supplier claim. Calculator pages are educational tools for laboratory planning and should be cross-checked against professional protocols, institutional requirements, and applicable laws. Legal and disclaimer pages explain the boundaries of PeptideStack content and the responsibility of visitors who evaluate third-party vendors. The rendered interface may add interactive details such as mobile navigation labels, product tabs, share buttons, related article cards, disclosure boxes, call-to-action buttons, vendor selectors, copy-code controls, email-code forms, footer navigation, and status labels. The static HTML fallback includes this context so the same page purpose is understandable before the JavaScript application finishes loading. Visitors should treat PeptideStack as a research and comparison starting point. Final supplier evaluation should include direct review of the external vendor website, current product availability, checkout terms, applicable laws, institutional requirements, and any third-party laboratory documentation available for the exact product or batch being considered. Footer resources repeat important sitewide context: PeptideStack is independent, affiliate-supported, research-focused, and not a pharmacy or manufacturer. Pages may include links to the iOS app, calculators, blog hubs, product hubs, supplier comparisons, support contact, and policy documents. This repeated context is intentionally available in the raw HTML for crawlers that inspect a page before executing the React bundle. Raw HTML also includes page summaries for mobile crawlers using JavaScript rendering, desktop crawlers comparing source to rendered output, accessibility tools, and no-script visitors. The fallback is replaced by the React app in normal browsers but keeps the source document aligned with the visible page topic. This fallback keeps source HTML and rendered HTML closer for crawl diagnostics and SEO audits across crawled pages, routes, reports, and recrawls.